Kura Oncology (KURA) Total Current Liabilities (2010 - 2026)

Kura Oncology (KURA) has 17 years of Total Current Liabilities data on file, last reported at $101.5 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 13.07% year-over-year to $101.5 million in Q1 2026; TTM through Mar 2026 was $101.5 million, a 13.07% increase from a year earlier, with the FY2025 full-year figure at $117.0 million, up 48.61% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $101.5 million, down from $117.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for KURA reached as high as $121.3 million in Q3 2025 and fell as low as $17.7 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $53.6 million across 5 years, with a median of $33.5 million in 2024.
• Across the five-year window, Total Current Liabilities decreased 29.49% in 2022 and surged 220.39% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $24.1 million in 2022, then soared by 46.58% to $35.3 million in 2023, then jumped by 123.21% to $78.7 million in 2024, then jumped by 48.61% to $117.0 million in 2025, then dropped by 13.23% to $101.5 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $101.5 million in Q1 2026, $117.0 million in Q4 2025, and $121.3 million in Q3 2025.